ReviewTransactions of the Royal Society of Tropical Medicine and Hygiene2019
Triclabendazole in the treatment of human fascioliasis: a review.
Review in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 122 citations in OpenAlex.
- Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals.Clinical and translational science · 2023Trial
- Genetic diversity and host-symbiont cophylogenetic analysis ofCurrent research in parasitology & vector-borne diseases · 2026Article
- A Stability-Indicating RP-HPLC Method for Simultaneous Determination of Triclabendazole and Levamisole in Oral Suspension Formulation.International journal of analytical chemistry · 2026Article
- Hepatic Fascioliasis Masquerading as Acute Appendicitis in a Child: A Case Report.Clinical medicine insights. Case reports · 2026Article
- Mitochondrial genome analysis supports zoonotic transmission of triclabendazole-resistant human fascioliasis in Peru.One health (Amsterdam, Netherlands) · 2025Article
- Article
- High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study.Tropical medicine and infectious disease · 2025Article
- Clinical, laboratory features and treatment outcomes of patients infected with Fasciola in Northern Vietnam, 2019-2023.Tropical diseases, travel medicine and vaccines · 2025Article
- Pancreatitis Manifestation and Mimicking Gallstone Symptoms Caused by Fasciola Hepatica: A Case Report.Middle East journal of digestive diseases · 2025Article
- Potentially pathogenic free-living amoebae at very high altitude: Detection by multiplex qPCR in the Northern Altiplano fascioliasis hyperendemic area in Bolivia.One health (Amsterdam, Netherlands) · 2025Article
- Unusual diagnosis in a Lebanese child with persistent hyper eosinophilia: a case report.Annals of medicine and surgery (2012) · 2025Article
- In Vitro Effects of Vanadate Erbium/Silver Oxide (ErVOVeterinary medicine and science · 2025Article
- Independent origins and non-parallel selection signatures of triclabendazole resistance in Fasciola hepatica.Nature communications · 2025Article
- The Clinical Picture Caused byOpen forum infectious diseases · 2025Article
- Article
- Hepatic eosinophilic pseudotumor due toWorld journal of hepatology · 2025Article
- Comparative analysis of anthelmintic treatments: impact on liver biomarkers and clinical recovery in sheep with fasciolosis.Frontiers in veterinary science · 2025Article
- Distinct gut microbiome features characterizeFrontiers in cellular and infection microbiology · 2025Article
- A QbD Approach for the Formulation and Control of Triclabendazole in Uncoated Tablets: From Polymorphs to Drug Formulation.Pharmaceutics · 2024Article
- UnderstandingToxicology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fascioliasis occurs on all inhabited continents. It is caused by Fasciola hepatica and Fasciola gigantica, trematode parasites with complex life cycles, and primarily affects domestic livestock. Humans become infected after ingestion of contaminated food (typically wild aquatic vegetables) or water. Fascioliasis may be difficult to diagnose as many symptoms are non-specific (e.g. fever, abdominal pain and anorexia). Treatment options are limited, with older effective therapies such as emetine and bithionol no longer used due to safety issues and unavailability, and most common anthelminthics having poor efficacy. Clinical trials conducted over a 25-year period, together with numerous case reports, demonstrated that triclabendazole has high efficacy in the treatment of human fascioliasis in adults and children and in all stages and forms of infection. Triclabendazole was approved for human use in Egypt in 1997 and in France in 2002 and a donation program for the treatment of fascioliasis in endemic countries was subsequently established by the manufacturer and administered by the World Health Organization. Here the published data on triclabendazole in the treatment of human fascioliasis are reviewed, with a focus on more recent data, in light of the 2019 US Food and Drug Administration approval of the drug for use in human infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.